MARKET

CLVS

CLVS

Clovis Oncology
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.58
-0.38
-6.38%
After Hours: 5.60 +0.02 +0.36% 19:57 01/15 EST
OPEN
5.96
PREV CLOSE
5.96
HIGH
5.98
LOW
5.57
VOLUME
5.27M
TURNOVER
--
52 WEEK HIGH
11.63
52 WEEK LOW
3.620
MARKET CAP
492.82M
P/E (TTM)
-1.0652
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Clovis Oncology (CLVS) Receives a Rating Update from a Top Analyst
H.C. Wainwright analyst Edward White maintained a Buy rating on Clovis Oncology (CLVS) today and set a price target of $15.00. The company's shares closed
SmarterAnalyst · 3d ago
Discover Pancreatic Cancer Drugs Market to grow at a much faster rate beyond 2020| Financial Analysis and Forecast
Jan 13, 2021 (WiredRelease via Comtex) -- Pancreatic Cancer Drugs Businesses must navigate the financial and operational challenges of coronavirus while...
marketresearch.biz · 4d ago
8-K: Clovis Oncology, Inc.
(EDGAR Online via COMTEX) -- false 0001466301 0001466301 2021-01-11 2021-01-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 5d ago
DJ Clovis Oncology Up 9% After Revenue Forecast
Dow Jones · 6d ago
Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M
Clovis Oncology (CLVS) expects global Q4 sales of Rubraca® (rucaparib) in the range of $43.0 to $43.5M ($39.3M last year) vs. a $38.8M in the prior quarter; sees FY2020 Rubraca
Seekingalpha · 6d ago
*DJ Clovis: Approximately $240M in Cash and Cash Equivalents at Dec 31
Dow Jones · 6d ago
*DJ Clovis Preliminary 4Q U.S. Pdt Rev of $36.3M-$36.7M; E.U. Rev $6.5M-$6.8M
Dow Jones · 6d ago
*DJ Clovis Oncology Preliminary 4Q Rubraca Global Sales $43.0M-$43.5M
Dow Jones · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLVS. Analyze the recent business situations of Clovis Oncology through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLVS stock price target is 7.33 with a high estimate of 15.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 295
Institutional Holdings: 59.12M
% Owned: 66.94%
Shares Outstanding: 88.32M
TypeInstitutionsShares
Increased
56
5.14M
New
50
2.67M
Decreased
42
2.46M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.21%
Key Executives
Chairman/Independent Director
Ginger Graham
President/Chief Executive Officer/Co-Founder/Director
Patrick Mahaffy
Co-Founder/Executive Vice President
Gillian Ivers-Read
Chief Financial Officer/Executive Vice President
Daniel Muehl
Executive Vice President/General Counsel
Paul Gross
Senior Vice President
C. Dale Hooks
Executive Vice President/Director of Human Resources
Ann Bozeman
Executive Vice President
Lindsey Rolfe
Independent Director
Brian Atwood
Independent Director
Robert Azelby
Independent Director
James Blair
Independent Director
Richard Fair
Independent Director
Keith Flaherty
Independent Director
Paul Klingenstein
Independent Director
Edward McKinley
Independent Director
Thorlef Spickschen
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CLVS
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Clovis Oncology Inc stock information, including NASDAQ:CLVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLVS stock methods without spending real money on the virtual paper trading platform.